Silk Road Medical Inc. provided earnings guidance for the quarter ended September 30, 2022. For the period, the company preliminary estimated revenue was $37.4 million, as compared to $24.7 million for the three months ended September 30, 2021, an increase of $12.7 million or 51% compared to three months ended September 30, 2021. The company's estimated net loss was between $10.2 million and $10.6 million, as compared to $13.9 million for the three months ended September 30, 2021, a decrease of between $3.3 million and $3.7 million or between 24% and 27%, compared to the three months ended September 30, 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.74 USD | +2.52% | +9.75% | +85.33% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+85.33% | 897M | |
-6.23% | 180B | |
+2.59% | 112B | |
-2.75% | 68.53B | |
+5.32% | 51.97B | |
+7.61% | 44.08B | |
+5.62% | 42.23B | |
+25.17% | 32.43B | |
+16.72% | 26.39B | |
-2.66% | 24.97B |
- Stock Market
- Equities
- SILK Stock
- News Silk Road Medical, Inc
- Silk Road Medical, Inc Provides Earnings Guidance for the Quarter Ended September 30, 2022